After the early withdrawal of rimonabant, a CB1 inverse agonist originally used to decrease body weight in obesity, from the pharmaceutical market because of safety concerns, the present preliminary study may predict the effectiveness of ghrelin receptor and CB1 neutral antagonists in the treatment of hyperphagia and bingeing on highly palatable foods in obesity. Here, CNR1 is linked to obesity due to melanocortin 4 receptor deficiency.